Article
PDT laser receives expedited review status
The FDA has accepted for filing and granted expedited review status to the Miravant Medical Technologies' premarket application for the IRIS Medical OcuLight 664 ophthalmic photodynamic therapy (PDT) laser used to activate drug SnET2, a proposed drug and light treatment for patients with wet age-related macular degeneration (AMD).
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
